ArticleInflammatory bowel diseases2015
The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease.
Article in Inflammatory bowel diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Anemia of Inflammation in Solid Tumor Patients and Practical Education for Oncologists and Nurses.Thoracic cancer · 2026Review
- Anemia of Chronic Disease: Pathophysiology, Diagnosis and Management.Hematology reports · 2026Review
- Inhibition of alternative complement system and prolyl hydroxylase ameliorates anaemia of inflammation.Inflammopharmacology · 2025Article
- Ferric carboxymaltose for anemia in Crohn's disease patients at a tertiary center: A retrospective observational cohort study.World journal of clinical cases · 2023Article
- Iron Status and Supplementation during Tuberculosis.Microorganisms · 2023Review
- Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease.Genome medicine · 2022Article
- Investigation of the effects of anti-TNF agents on hemoglobin levels in patients with inflammatory bowel disease.Medicine · 2022Article
- Physiology and Inflammation Driven Pathophysiology of Iron Homeostasis-Mechanistic Insights into Anemia of Inflammation and Its Treatment.Nutrients · 2021Review
- Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases.Journal of clinical medicine · 2020Article
- Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency.Advances in therapy · 2020Review
- Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents.Therapeutic advances in gastroenterology · 2020Article
- Anemia of inflammation.Blood · 2019Review
- Anti-TNF-Mediators of inflammation · 2019Article
- Established and Emerging Concepts to Treat Imbalances of Iron Homeostasis in Inflammatory Diseases.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Changes in Hepcidin and Hemoglobin After Anti-TNF-alpha Therapy in Children and Adolescents With Crohn Disease.Journal of pediatric gastroenterology and nutrition · 2018Article
- Short-Term Outcome of Infliximab Therapy in Pediatric Crohn's Disease: A Single-Center Experience.Pediatric gastroenterology, hepatology & nutrition · 2017Article
- Surgical Treatment of Crohn Colitis Involving More Than 2 Colonic Segments: Long-Term Outcomes From a Single Institution.Medicine · 2016Observational
- Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease.Digestive diseases and sciences · 2016Article
- Persistent or Recurrent Anemia Is Associated With Severe and Disabling Inflammatory Bowel Disease.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAnti-tumor necrosis factor (TNF) agents are an important component of inflammatory bowel disease (IBD) treatment, but data on their influence on anemia, a frequent complication of IBD, are limited. The aim of this study was to evaluate the effect of anti-TNF agents on hemoglobin (Hb) levels in a large IBD cohort.
methodsProspectively collected demographic, clinical, laboratory, and treatment data from IBD patients who started anti-TNF treatment at a tertiary referral center during the years 2010 to 2012 were analyzed. Follow-up data including disease activity scores (Harvey-Bradshaw index or ulcerative colitis activity index), quality of life scores (short IBD questionnaire) completed at each visit, and laboratory data were analyzed. Data from the year of anti-TNF initiation (yr 0) to the following year (yr 1) were compared.
resultsA total of 430 IBD patients (324 with Crohn's disease, 51.6% females) started anti-TNF treatment. The prevalence of anemia and median Hb levels did not change between years 0 and 1. Median short IBD questionnaire was significantly improved at year 1 (P = 0.002). IBD patients with anemia had significantly higher median Hb levels at year 1 compared with year 0 (P = 0.0009). Hematopoietic response (increase of Hb ≥2 g/dL) was observed in only 33.6% of the 134 anemic IBD patients, despite iron replacement being administered in 126 anemic patients (oral, 77%). Improvement in Hb levels was independently significantly correlated with change of C-reactive protein levels (P = 0.04) and immunomodulator use (P = 0.03).
conclusionsAnemia remains a significant manifestation of IBD 1 year after treatment with anti-TNF agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.